3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
5
Melanoma
4
Carcinoma, Renal Cell
4
Lymphoma, Follicular
3
Lymphoma
3
Sarcoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Zollinger-Ellison Syndrome
1
Virus Diseases
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Philadelphia Chromosome
1
Multiple Myeloma
1
Meningeal Carcinomatosis
1
Lymphoproliferative Disorders
1
Lymphomatoid Granulomatosis
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Influenza, Human
1
Gastrointestinal Cancer Metastatic
1
Epstein-Barr Virus Infections
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Carcinoma in Situ
1
Interventions
Gemcitabine
157
Cisplatin
116
pembrolizumab
80
Nivolumab
42
Carboplatin
42
Paclitaxel
41
Mitomycin
41
Cystectomy
40
Docetaxel
38
atezolizumab
33
Magnetic Resonance Spectroscopy
31
durvalumab
30
Radiotherapy
29
BCG Vaccine
26
avelumab
24
Specimen Handling
24
Doxorubicin
23
enfortumab vedotin
22
Fluorouracil
20
Cystoscopy
20
Methotrexate
17
Vinblastine
16
Standard of Care
15
Filgrastim
14
Transurethral Resection of Bladder
13
Sunitinib
13
Ipilimumab
13
vinflunine
12
5-aminolevulinic acid hexyl ester
12
tremelimumab
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urinary Bladder Neoplasms
×
Interferons
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled